Form 4: Beam Therapeutics Director Receives Stock Option Grant

Director Kathleen E. Walsh was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Summary

• Director Kathleen E. Walsh received a grant of 19,676 stock options on June 3, 2026.
• The options have an exercise price of $29.55 per share.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Beam Therapeutics common stock.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact for shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Beam Therapeutics, BEAM, Director, Stock Options, Insider Trading, Equity Compensation